



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/706,496		11/12/2003	Benjamin Oshlack	200.93311CON8	7218
20583	7590	09/17/2004		EXAM	INER
JONES DA	λY			WEBMAN,	EDWARD J
222 EAST 4 NEW YOR		0017		ART UNIT PAPER NUMBER	
NEW TORK	ic, 111 1	0017		1617	
				DATE MAIL ED: 00/17/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FILING DATE

FIRST NAMED APPLICANT

OFFICE ACTION SUMMARY

ATTY. DOCKET NO.

+ U.S. GPO: 1996-421-632/40206

 EXAMINER		

DATE MAILED:

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

Notice of Informal Patent Application, PTO-152

PTOL-326 (Rev. 9/96)

11/12/03 Responsive to communication(s) filed on This action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 D.C. 11; 453 O.G. 213. A shortened statutory period for response to this action is set to expire ______ month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a). Disposition of Claims is/are pending in the application. Claim(s) is/are withdrawn from consideration. Of the above, claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction or election requirement. Claim(s) **Application Papers** See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948. is/are objected to by the Examiner. The drawing(s) filed on _is _ approved _ disapproved. The proposed drawing correction, filed on _ The specification is objected to by the Examiner. The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). ☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been received. received in Application No. (Series Code/Serial Number) received in this national stage application from the International Bureau (PCT Rule 17.2(a)). *Certified copies not received: __ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) Notice of Reference Cited, PTO-892 \square Information Disclosure Statement(s), PTO-1449, Paper No(s). $\frac{(1/12/o)}{3}$ ☐ Interview Summary, PTO-413 Notice of Draftperson's Patent Drawing Review, PTO-948

-SEE OFFICE ACTION ON THE FOLLOWING PAGES--

Application/Control Number: 10/706,496

Art Unit: 1617

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldie et al in view of Zierenberg et al.

Goldie et al teach controlled release of hydromorphone (oxycodone) hydrochloride (title). Acrylic polymers are specified (column 2 line 56). Tablets are specified (column 2 line 40). 2-40mg drug is disclosed (column 2 line 43).

Zierenberg et al teach a delayed release tablet comprising an acrylic polymer and a second polymer such as polyvinylpyrolidone to vary the rate of release (column 2 lines 46-48, column 2 line 67-column 3 line 8). Up to 50 mg of active is specified (column 3 lines 15-20). Compression is specified (column 4 line 10).

It would have been obvious to one of ordinary skill to add polyvinylpyrolidone to the composition of Goldie et al to achieve the beneficial effect of varying the rate of release in view of Zierenberg et al.

Claims 1-2 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldie in view of Hill.

Goldie et al is discussed above.

Hill teach a controlled release tablet comprising a carboxy vinyl polymer and polymeric vinyl pyrolidone (abstract). Compression is specified (column 2 line 43). A wide variety of medicaments is disclosed (column 2 line 54).

Page 3

Application/Control Number: 10/706,496

Art Unit: 1617

It would have been obvious to one of ordinary skill to add polyvinylpyrolidone to the composition of Goldie et al to achieve the additional effect of a second control release agent to the acrylic polymer of Goldie et al in view of Hill. In re Kerkhoven 626 F.2d 846 (CCPA 1980).

No claims allowed.

Any inquiry concerning this communication should be directed to Edward J. Webman at telephone number 571-272-0633.

Webman/tgd

August 18, 2004

EDWARD J. VIESMAN PRIMARY EXAMINER GROUP 1500